COVID-19 Vaccines
Pfizer and BioNTech COVID-19 vaccine approved for use in children 5 to 11 years of age.
Researchers analyzed historical and current data from Olmsted County, Minnesota and found the incidence of cerebral venous sinus thrombosis (CVST) had increased in females who received the J&J COVID-19 vaccine. The highest incidence of CVST was in women 40-49, followed by women aged 30 to 39 years. CDC analysts compared the outcomes of 20,101 fully vaccinated immunocompromised adults to 69,116 fully vaccinated immunocompetent adults and found vaccine effectiveness to prevent COVID-19 related hospitalizations to be 77% for immunocompromised adults compared to 90% for immunocompetent adults. This decrease in effectiveness was present regardless of the type of vaccine used, patient’s geographic location, prevalence of the Delta variant or underlying cause for the immunocompromised state. Comments are closed.
|
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker
Archives
January 2023
Categories |
Services |
Company |
|
© COPYRIGHT 2015. ALL RIGHTS RESERVED.
|